BioSpace News Archive

Business

Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck

Nerviano Medical Sciences S.r.l. announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293.

September 21, 2022
·
5 min read
Genetown

Publication Describes New International Consortium Standardizing Immunohistochemistry

Boston Cell Standards, a company standardizing tumor tissue testing with the first immunohistochemistry laboratory reference standards, announced the publication of a journal article summarizing the vital mission of the newly launched Consortium for Analytic Standardization in Immunohistochemistry (CASI).

September 21, 2022
·
4 min read
Business

Foundation Medicine and Day One Biopharmaceuticals Announce Global Collaboration to Advance Pediatric Cancer Care

Foundation Medicine, Inc. and Day One Biopharmaceuticals today announced a collaboration to develop FoundationOne®CDx as a companion diagnostic for Day One’s lead investigational therapy, tovorafenib (DAY101).

September 21, 2022
·
9 min read
Drug Development

Atsena Therapeutics Announces Late-Breaker Presentation at the American Academy of Ophthalmology 2022 Annual Meeting

Atsena Therapeutics today announced that data from the Phase I/II clinical trial of ATSN-101 will be presented in a Late Breaking Developments session during the Retina Subspecialty Day.

September 21, 2022
·
1 min read
Deals

Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning

Intercept Pharmaceuticals, Inc. today announced a summary of the actions it has taken to improve its capital position, including the recently announced private repurchases of senior secured convertible notes.

September 21, 2022
·
2 min read
Business

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP).

September 21, 2022
·
3 min read
Business

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor

MaxCyte, Inc. announced that it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, within Maryland’s I-270 Biotech Corridor.

September 21, 2022
·
4 min read
Drug Development

Mapi Pharma Announces Positive Top-Line Results from GA Depot Phase III Trial for Relapsing forms of Multiple Sclerosis (RMS)

Mapi Pharma Ltd. announced today positive top-line results from the GA Depot (a long acting glatiramer acetate) Phase III clinical trial assessing the efficacy, safety and tolerability of a once monthly GA Depot 40 mg compared to placebo in relapsing forms of multiple sclerosis (RMS) patients.

September 21, 2022
·
5 min read
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting

Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting.

September 21, 2022
·
7 min read
BioMidwest

BrightInsight and bioMérieux Announce Partnership to Launch Clinical Digital Solutions for Diagnostics

BrightInsight, Inc. and bioMérieux announced a partnership to develop and bring to market a Clinical Digital Solution for diagnostics enabling clinical decision support for disease areas across their diagnostic tests.

September 21, 2022
·
4 min read